Roche (RHHBY.US) enters cancer drug development collaboration, may invest over $1.8 billion
1min read Flare Therapeutics recently announced a strategic discovery collaboration with Roche (RHHBY.US). The collaboration will leverage Flare Therapeutics' proteomics and mass spectrometry platform and its proprietary electrophilic compound library to discover new small molecule drugs targeting undruggable transcription factor targets in oncology. As part of the collaboration, Flare Therapeutics will receive a $70 million upfront payment and is eligible to receive potential milestone payments of up to $1.8 billion for discovery, development, and commercialization.
Under the collaboration, Flare Therapeutics will lead the discovery and preclinical activities for multiple transcription factor targets in oncology, while Roche will leverage its expertise in oncology to further develop the potential products in preclinical, clinical development, and commercialization activities.
Flare Therapeutics is a biotechnology company focused on developing drugs targeting transcription factors. Since its inception, Flare Therapeutics has rapidly established its emerging pipeline, including its lead program FX-909, a small molecule inhibitor targeting PPARG, a potential "first-in-class" oral agent. PPARG is a major regulator of the luminal lineage cells in advanced urothelial carcinoma, and FX-909 is currently in a Phase 1 study.